Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Enclomiphene | hCG (Human Chorionic Gonadotropin) | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism. | Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance. |
| Timing | Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation. | Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days. |
| Cycle Duration | Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months. | Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery. |
| Evidence Level | moderate_human | strong_human |
Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.
Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.
Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.
Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.
hCG mimics luteinizing hormone (LH) by binding the LH/CG receptor on testicular Leydig cells, activating the cAMP-PKA signaling cascade that upregulates steroidogenic acute regulatory protein (StAR) and CYP11A1, driving cholesterol conversion to pregnenolone and downstream testosterone synthesis. By maintaining intratesticular testosterone (ITT) levels during exogenous testosterone administration, hCG preserves Leydig cell function, spermatogenesis, testicular volume, and the production of neurosteroids (pregnenolone, DHEA) and estradiol within the testes.
Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance.
Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days.
Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →